Biodegradable and Stimuli-Responsive Nanomaterials for Targeted Drug Delivery in Autoimmune Diseases
Journal of Functional Biomaterials,
Год журнала:
2025,
Номер
16(1), С. 24 - 24
Опубликована: Янв. 14, 2025
Autoimmune
diseases
present
complex
therapeutic
challenges
due
to
their
chronic
nature,
systemic
impact,
and
requirement
for
precise
immunomodulation
avoid
adverse
side
effects.
Recent
advancements
in
biodegradable
stimuli-responsive
nanomaterials
have
opened
new
avenues
targeted
drug
delivery
systems
capable
of
addressing
these
challenges.
This
review
provides
a
comprehensive
analysis
state-of-the-art
nanocarriers
such
as
polymeric
nanoparticles,
liposomes,
hydrogels
engineered
autoimmune
therapies.
These
are
designed
degrade
safely
the
body
while
releasing
agents
response
specific
stimuli,
including
pH,
temperature,
redox
conditions,
enzymatic
activity.
By
achieving
localized
controlled
release
anti-inflammatory
immunosuppressive
agents,
minimize
toxicity
enhance
efficacy.
We
discuss
underlying
mechanisms
nanomaterials,
recent
applications
treating
rheumatoid
arthritis,
multiple
sclerosis,
inflammatory
bowel
disease,
design
considerations
essential
clinical
translation.
Additionally,
we
address
current
challenges,
biocompatibility,
scalability,
regulatory
hurdles,
well
future
directions
integrating
advanced
nanotechnology
with
personalized
medicine
treatment.
highlights
transformative
potential
presenting
them
promising
strategy
advance
precision
improve
patient
outcomes
disease
management.
Язык: Английский
Machine learning-assisted rheumatoid arthritis formulations: A review on smart pharmaceutical design
Materials Today Communications,
Год журнала:
2024,
Номер
41, С. 110208 - 110208
Опубликована: Авг. 27, 2024
Язык: Английский
miRNA let-7f-5p-encapsulated labial gland MSC-derived EVs ameliorate experimental Sjögren’s syndrome by suppressing Th17 cells via targeting RORC/IL-17A signaling axis
Journal of Nanobiotechnology,
Год журнала:
2025,
Номер
23(1)
Опубликована: Март 20, 2025
Sjögren's
syndrome
(SS)
is
an
autoimmune
disease
primarily
affecting
salivary
glands,
with
xerostomia
as
a
distinct
clinical
manifestation.
This
also
poses
significantly
increased
risk
of
lymphoma,
severely
impacting
patients'
quality
life.
The
imbalance
between
Th17
and
Treg
cells
plays
critical
role
in
SS
progression,
driving
severe
immune
dysregulation,
chronic
inflammation,
escalating
tissue
dysfunction.
However,
current
treatments
for
still
remain
limited,
it
continues
to
be
recognized
refractory
disease.
Therefore,
the
development
novel
effective
therapeutic
strategies
pressing
demand
research.
In
recent
years,
extracellular
vesicle
(EV)
therapy
has
emerged
promising
approach
treatment,
showing
encouraging
outcomes
modulating
balance
alleviating
symptoms.
EVs
carry
diverse
cargo,
among
which
microRNAs
(miRNAs)
are
highly
abundant
play
roles.
These
small
RNAs
essential
EV-mediated
functions,
particularly
regulating
gene
expression
microenvironment.
Our
research
team
first
isolated
labial
gland
mesenchymal
stem
(LGMSCs)
their
derived
(LGMSC-EVs),
offer
potential
advantages
due
origin.
Then
we
screened
identified
enriched
miRNA
let-7f-5p
key
regulator
through
profiling
analysis.
To
achieve
better
outcomes,
transfected
exogenous
into
LGMSC-EVs
upregulate
its
expression,
thereby
constructing
let-7f-5p-encapsulated
LGMSC-EVs.
modified
were
subsequently
tested
experimental
mouse
model
evaluate
potential.
upregulation
enhanced
effects,
resulting
improvements
such
flow
reduced
lymphocytic
infiltration.
Mechanistically,
suppressed
by
directly
targeting
3'-untranslated
region
(3'UTR)
RORC,
inhibiting
RORC/IL-17A
signaling
axis,
reducing
IL-17A
production,
restoring
Th17/Treg
promoting
anti-inflammatory
profile.
Collectively,
this
LGMSC-EV
offers
target-driven
treatment
SS,
achieving
improved
rebalance
after
modification
let-7f-5p,
presents
new
SS.
Язык: Английский
Tetracyclines in Rheumatoid Arthritis: Dual Anti-Inflammatory and Immunomodulatory Roles, Effectiveness, and Safety Insights
Antibiotics,
Год журнала:
2025,
Номер
14(1), С. 65 - 65
Опубликована: Янв. 10, 2025
Rheumatoid
arthritis
(RA)
is
a
chronic
autoimmune
disease
characterized
by
persistent
inflammation,
joint
pain,
and
progressive
cartilage
bone
erosion.
Despite
advancements
in
RA
management
with
disease-modifying
antirheumatic
drugs
(DMARDs)
biologics,
some
patients
remain
refractory
to
conventional
treatments.
Tetracyclines,
such
as
minocycline
doxycycline,
exhibit
anti-inflammatory
immunomodulatory
properties,
making
them
potential
supplementary
This
narrative
review
explores
their
effectiveness,
mechanisms
of
action,
safety
profiles,
current
challenges
care.
Tetracyclines
have
demonstrated
significant
effects,
including
the
inhibition
pro-inflammatory
cytokines
matrix
metalloproteinases
(MMPs),
which
are
critical
pathology.
Clinical
trials,
double-blind,
placebo-controlled
studies,
shown
efficacy
reducing
symptoms,
particularly
early
cases.
However,
use
remains
limited
inconsistent
evidence,
small
sample
sizes,
concerns
about
antimicrobial
resistance.
Current
guidelines
for
do
not
explicitly
recommend
tetracyclines
due
these
limitations,
although
off-label
may
be
considered
specific
The
tetracycline
restricted
drug
interactions
causing
bacterial
resistance
alongside
unpredictable
patient
responses,
hence
necessity
prudence
its
prescription
within
clinical
setting.
To
overcome
development
safer
compounds,
in-depth
silico
analyses,
integration
personalized
medicine
approaches
needed.
Overall,
show
promise
adjunct
therapies
dual
actions.
highlights
need
further
research
address
gaps
modified
reduced
effects
improved
well
optimize
outcomes.
Язык: Английский
Emerging Mechanisms and Biomarkers Associated with T-Cells and B-Cells in Autoimmune Disorders
Clinical Reviews in Allergy & Immunology,
Год журнала:
2025,
Номер
68(1)
Опубликована: Фев. 11, 2025
Язык: Английский
Polymer-modified DNA hydrogels for living mitochondria and nanozyme delivery in the treatment of rheumatoid arthritis
Bioactive Materials,
Год журнала:
2025,
Номер
47, С. 448 - 459
Опубликована: Фев. 12, 2025
Язык: Английский
Increased Alleviation of Bone Destruction in Individuals with Rheumatoid Arthritis via the Coinhibition of the METTL3 and YTHDF1 Axis by the Combination of Triptolide and Medicarpin
Engineering,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 1, 2025
Язык: Английский
Applications of Matrix Metalloproteinase-9-Related Nanomedicines in Tumors and Vascular Diseases
Pharmaceutics,
Год журнала:
2025,
Номер
17(4), С. 479 - 479
Опубликована: Апрель 7, 2025
Matrix
metalloproteinase-9
(MMP-9)
is
implicated
in
tumor
progression
and
vascular
diseases,
contributing
to
angiogenesis,
metastasis,
extracellular
matrix
degradation.
This
review
comprehensively
examines
the
relationship
between
MMP-9
these
pathologies,
exploring
underlying
molecular
mechanisms
signaling
pathways
involved.
Specifically,
we
discuss
contribution
of
epithelial–mesenchymal
transition,
as
well
its
involvement
a
spectrum
including
macrovascular,
cerebrovascular,
ocular
diseases.
focuses
on
recent
advances
MMP-9-targeted
nanomedicine
strategies,
highlighting
design
application
responsive
nanoparticles
for
enhanced
drug
delivery.
These
nanotherapeutic
strategies
leverage
overexpression
achieve
targeted
release,
improved
penetration,
reduced
systemic
toxicity.
We
explore
various
nanoparticle
platforms,
such
liposomes
polymer
nanoparticles,
their
action,
degradation,
targeting
specificity.
Finally,
address
challenges
posed
by
heterogeneity
expression
implications
personalized
therapies.
Ultimately,
this
underscores
diagnostic
therapeutic
potential
nanomedicines
against
tumors
Язык: Английский